Literature DB >> 521836

Alterations in [3H]spiperone binding in human caudate nucleus, substantia nigra and frontal cortex in the Shy-Drager syndrome and Parkinson's disease.

M Quik, E G Spokes, A V Mackay, R Bannister.   

Abstract

[3H]Spiperone binding was investigated in the caudate nucleus, substantia nigra (s. nigra) and frontal cortex of control subjects and of patients with Parkinson's disease and the Shy-Drager syndrome. Binding sites for [3H]spiperone were interpreted as dopamine receptors in caudate and s. nigra, and as 5-hydroxytryptamine (5-HT) receptors in frontal cortex. Scatchard analysis showed that the Bmax (maximal number of binding sites) in caudate was similar in the 3 groups, whereas in s. nigra the Bmax was reduced by approximately 60% in both Parkinsons disease and Shy-Drager syndrome. The dissociation constant (Kd) for [3H]spiperone binding in s. nigra was similar in the 3 groups. In caudate nucleus, the Kd was similar in control and Parkinson groups; however, there was a significant increase in the dissociation constant in the caudate nucleus from cases of Shy-Drager syndrome. No differences in binding characteristics were observed in the frontal cortex. These results are taken to reflect a loss of dopamine receptor sites in the s. nigra in both Parkinson's disease and Shy-Drager syndrome, and a reduced affinity of dopamine receptor sites in the caudate nucleus in Shy-Drager syndrome.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 521836     DOI: 10.1016/0022-510x(79)90021-2

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  8 in total

Review 1.  Multiple system atrophy: pathophysiology and management.

Authors:  G K Wenning; S Braune
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  Pharmacological implications for neuroreceptor imaging.

Authors:  N P Verhoeff
Journal:  Eur J Nucl Med       Date:  1991

3.  The use of lisuride in the treatment of multiple system atrophy with autonomic failure (Shy-Drager syndrome).

Authors:  A J Lees; R Bannister
Journal:  J Neurol Neurosurg Psychiatry       Date:  1981-04       Impact factor: 10.154

4.  Multiple system atrophy: natural history, MRI morphology, and dopamine receptor imaging with 123IBZM-SPECT.

Authors:  J B Schulz; T Klockgether; D Petersen; M Jauch; W Müller-Schauenburg; S Spieker; K Voigt; J Dichgans
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-09       Impact factor: 10.154

5.  L-dopa reverses the elevated density of D2 dopamine receptors in Parkinson's diseased striatum.

Authors:  M Guttman; P Seeman
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

6.  Predictors for improvement after electroconvulsive therapy in parkinsonian patients with on-off symptoms.

Authors:  J Balldin; A K Granérus; G Lindstedt; K Modigh; J Wålinder
Journal:  J Neural Transm       Date:  1981       Impact factor: 3.575

7.  Dopamine D1 receptors in Parkinson's disease and striatonigral degeneration: a positron emission tomography study.

Authors:  H Shinotoh; O Inoue; K Hirayama; A Aotsuka; M Asahina; T Suhara; T Yamazaki; Y Tateno
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-05       Impact factor: 10.154

Review 8.  mGlu5, Dopamine D2 and Adenosine A2A Receptors in L-DOPA-induced Dyskinesias.

Authors:  Nicolas Morin; Marc Morissette; Laurent Grégoire; Thérèse Di Paolo
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.